Proper time interval between alfentanil and rocuronium administration for preventing rocuronium-induced withdrawal movement

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100045137

Enrollment

Unknown

Registered

2021-04-07

Start date

2021-05-01

Completion date

Unknown

Last updated

2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rocuronium-induced withdrawal movement

Interventions

Male:Nil

Female:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Patients aged 18-65 years; 2.BMI 18~28 kg/m2; 3.ASA physical status I or II; 4.The subjects understood and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1.Body weight > 75 kg or < 50 kg; 2.Patients with cardiopulmonary diseases, allergic to anesthetics, asthma patients and patients who have used analgesics and sedatives within 24 hours.

Design outcomes

Primary

Measure	Time frame
the time interval between alfentanil and rocuronium administration at which there was a 50% probability of preventing rocuronium-induced withdrawal movement;	—

Secondary

Measure	Time frame
Mean arterial pressure, heart rate; rigidity, bradycardia, and hypotension;	—

Countries

China

Contacts

Public ContactWang Xiaodan

Department of Anesthesiology, Taizhou Hospital of Zhejiang Province

wangxd8905@enzemed.com+86 15958663558

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026